RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
NJCTTQ, a Nanjing pharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts. NJCTTQ will have China and Thai rights to multiple immunotherapies discovered by Abpro’s DiversImmune™ antibody discovery platform for T-cell engagement. NJCTTQ will make a $60 million near-term payment to Abpro to underwrite R&D expenses and be responsible for the remainder in milestones and royalties. NJCTTQ is a subsidiary of CTTQ Pharma, a division of Sino Biopharm.
Source: China Biotoday
